Trial Profile

Pivotal study of INZ-701 in pediatric patients with ENPP1 Deficiency

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INZ-701 (Primary)
Indications Calcinosis
Focus Pharmacodynamics; Registrational
Acronyms ENERGY-2

Most Recent Events

06 Aug 2024 According to an Inozyme Pharma media release, initiation of this pivotal trial in infants in ex US is expected in Q4 2024.
12 Mar 2024 According to an Inozyme Pharma media release, the company anticipate to initiate this trial in 2H 2024.
31 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com